Under the first batch of 2 DG (2-deoxy-D-glucose), a new Defense Research and Development Organization (DRDO) drug for Corona-infected patients, 10,000 doses on Monday were protected by Defense Minister Rajnath Singh (Defense Minister Rajnath Singh) and Union Health Minister Harshvardhan presented. After three trials, its emergency use was approved by DCGI on May 1, 2021. In the powder, the drug will be given in a bag to be disposed of in the water. It is able to stop the growth of the virus by visiting infected cells.
Details of this are provided on Twitter by the Office of the Minister of Defense. It was reported that the first load of the drug will be released by the Minister of Defense at a video conference at 10.30 today. The drug was developed by the Nuclear Medicine Institute and Allied Sciences (INMAS) of DRDO in collaboration with Doctor Reddy Lab.
Last Friday, ANI was informed by a DRDO official that the first batch of 1000 doses of 2DG drug would be released next week and could be given to Kovid patients. DRDO officials also said, ‘Drug manufacturers are working to speed up the production process for reuse. DRDO scientists, including Dr Anant Narayan Bhatt, are contributing to the development of the drug. ‘The clinical trial of this drug has been done and the results have been positive. Studies have shown that these cells help to speed up the recovery of hospitalized patients and reduce the dependence on excessive air. At the request of Prime Minister Narendra Modi for preparations to combat the disease, the DRDO decided to develop the drug.
In April 2020, during the first wave of the epidemic, INMAS-DRDO scientists began collaborating with the help of the CCMB (Center for Cellular and Molecular Biology), Hyderabad, and the molecules were found to be active in the SARS-CoV-2 virus. and They can stop the increase. Based on these results, DCGI approved its Phase 2 clinical trial in May 2020. The second phase of the trial ran from May to October last year and had very positive results. The case was heard in two parts, the first of which included 6 hospitals and the second of 11 local hospitals. In this case, the drug was given to 110 patients and good results came out. As a result, DCGI also approved a third clinical trial conducted in 27 hospitals from December 2020 to March 2021 in 220 patients. These hospitals are Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana,